论文部分内容阅读
2003年7月,FDA批准安进公司和惠氏制药的Enbrel (依那西普,etanercept) 的新适应证,即用于改善中至重度进行性类风湿性关节炎(RA) 患者的运动机能。本品由安进公司研制,安进和惠氏制药共同销售。本品已被FDA批准用于治疗银屑病性关节炎和强直性脊椎炎。本品还获FDA许可用于缓解
In July 2003, the FDA approved new indications for Enbrel (etanercept) from Amgen and Wyeth to improve motor function in patients with moderate to severe progressive rheumatoid arthritis (RA). The product developed by Amgen, Amgen and Wyeth Pharmaceutical co-sales. This product has been FDA approved for the treatment of psoriatic arthritis and ankylosing spondylitis. This product is also FDA approved for ease